Fish oil: safety and interactions
Tolerability, warfarin and risks observed in omega-3 studies.
Key points
- Fish oil can cause an unpleasant aftertaste and digestive complaints. If allergic to fish, check the origin of the specific product. [1] [2] [3] [4] See the evidence 1 2
- If taking warfarin or other medicines that reduce blood clotting, discuss the supplement and monitoring with a healthcare professional. When starting, stopping or changing a fish oil dose, agree on INR monitoring and do not change the warfarin dose yourself. [2] [3] [4] See the evidence 1 2
- In a review of long-term studies of different marine omega-3 preparations, atrial fibrillation was recorded more often; the signal was stronger at doses above 1 g daily. Most participants had cardiovascular risk. [5] See the evidence 1
- In a study of adults aged 50 and over, new or recurrent depression or significant symptoms were recorded more often with 1 g fish oil daily than placebo. Mean mood score did not differ clearly. [6] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Consider product composition, medicines and study results for specific doses.
Key points
Why these conclusions
Tolerability and observed risks
An unpleasant aftertaste and digestive upset are possible. If allergic to fish, consider supplement origin: a small study of two products does not establish safety of all preparations. [1] [2] [3] [4]
In VITAL-DEP, adults aged 50 and over taking 1 g fish oil daily had 651 versus 583 new or recurrent cases of depression or significant symptoms over a median 5.3 years; mean mood score did not differ clearly. [6]
In ORIP during pregnancy, approximately 800 mg DHA and 100 mg EPA daily was associated with more infants above the 97th birth-weight percentile for gestational age and sex: relative risk 1.30. This was a secondary outcome without interval adjustment for multiple comparisons. [7]
In a meta-analysis of seven long-term trials of different marine omega-3 preparations, atrial fibrillation was recorded more often; hazard ratio 1.25, with a stronger signal at doses above 1 g daily. [5]
A pooled analysis of different omega-3 preparations found no increase in bleeding; for high-dose prescription purified EPA the relative risk was 1.50, absolute difference about 0.6 percentage points. These results concern different preparations. [1] [2]
In a small study of people on warfarin, no clear INR difference from placebo was found. When starting, stopping or changing a fish oil dose, agree on INR monitoring with a professional and do not change the warfarin dose yourself. [2] [3]
In VITAL-DEP, among 18,353 adults aged 50 and over, 1 g fish oil daily (465 mg EPA and 375 mg DHA) over a median 5.3 years was associated with more new or recurrent cases of depression or significant symptoms: 651 versus 583, HR 1.13 (95% CI 1.01–1.26); mean mood score did not differ clearly.
In VITAL-DEP, among 18,353 adults aged 50 and over, 1 g fish oil daily (465 mg EPA and 375 mg DHA) over a median 5.3 years was associated with more new or recurrent cases of depression or significant symptoms: 651 versus 583, HR 1.13 (95% CI 1.01–1.26); mean mood score did not differ clearly. [6]
In ORIP, fish oil containing approximately 800 mg DHA and 100 mg EPA daily during pregnancy was associated with more infants above the 97th percentile of birth weight for gestational age and sex: adjusted relative risk 1.30 (95% CI 1.02–1.65). This was a secondary outcome; the CI was not adjusted for multiple comparisons.
In ORIP, fish oil containing approximately 800 mg DHA and 100 mg EPA daily during pregnancy was associated with more infants above the 97th percentile of birth weight for gestational age and sex: adjusted relative risk 1.30 (95% CI 1.02–1.65). This was a secondary outcome; the CI was not adjusted for multiple comparisons. [7]
In a meta-analysis of 7 large long-term trials of different marine omega-3 preparations (81,210 participants, mostly with cardiovascular risk), atrial fibrillation was recorded more often: HR 1.25 (95% CI 1.07–1.46); the signal was stronger above 1 g/day.
In a meta-analysis of 7 large long-term trials of different marine omega-3 preparations (81,210 participants, mostly with cardiovascular risk), atrial fibrillation was recorded more often: HR 1.25 (95% CI 1.07–1.46); the signal was stronger above 1 g/day. [5]
Fish oil can cause an unpleasant aftertaste and digestive upset. A pooled analysis of RCTs of different omega-3 preparations found no increase in bleeding; for high-dose prescription purified EPA the bleeding RR was 1.50 (95% CI 1.13–1.99), with an absolute difference of about 0.6 percentage points.
Fish oil can cause an unpleasant aftertaste and digestive upset. A pooled analysis of RCTs of different omega-3 preparations found no increase in bleeding; for high-dose prescription purified EPA the bleeding RR was 1.50 (95% CI 1.13–1.99), with an absolute difference of about 0.6 percentage points. [1] [2]
If taking warfarin or other anticoagulants, discuss the supplement and monitoring with a healthcare professional. If allergic to fish, consider product origin: a study of two supplements in six fish-sensitive people does not prove all products safe.
If taking warfarin or other anticoagulants, discuss the supplement and monitoring with a healthcare professional. If allergic to fish, consider product origin: a study of two supplements in six fish-sensitive people does not prove all products safe. [2] [3] [4]
Warfarin: Fish oil may change INR when taken with warfarin. In a small RCT with 16 enrolled participants, five of whom dropped out, no clear INR difference from placebo was detected over four weeks; the result applies to the products and conditions studied. When starting, stopping or changing a fish oil dose, tell the professional monitoring warfarin the product composition and dose and agree on INR monitoring; do not change the warfarin dose yourself.
Warfarin: Fish oil may change INR when taken with warfarin. In a small RCT with 16 enrolled participants, five of whom dropped out, no clear INR difference from placebo was detected over four weeks; the result applies to the products and conditions studied. When starting, stopping or changing a fish oil dose, tell the professional monitoring warfarin the product composition and dose and agree on INR monitoring; do not change the warfarin dose yourself. [2] [3]
In VITAL-DEP, new or recurrent depression or clinically significant symptoms were recorded more often in older adults taking fish oil.
| Parameter | Data |
|---|---|
| Result | In VITAL-DEP, new or recurrent depression or clinically significant symptoms were recorded more often in older adults taking fish oil. |
| Participants | Adults aged 50 and over without active depression or clinically significant symptoms at baseline |
| Form | Fish oil with specified EPA and DHA composition |
| Dose | 465 mg EPA and 375 mg DHA in 1 g oil daily |
| Dose basis | 465 mg EPA and 375 mg DHA in 1 g oil daily |
| Comparator | Placebo |
| Duration | Median 5.3 years |
| Confidence | 3/4: No additional substantial risk was established for this contrast.; No grounds for a separate downgrade.; Measurement directly addresses the specified narrow PICO.; The lower HR bound is close to 1 and permits a minimal change.; No specific data for a separate downgrade. |
| Evidence base | 1 randomized VITAL-DEP trial; 1 named publication on this outcome. |
| Sources | [6] |
In ORIP, birth weight above the 97th percentile was recorded more often with fish oil. This was a secondary outcome.
| Parameter | Data |
|---|---|
| Result | In ORIP, birth weight above the 97th percentile was recorded more often with fish oil. This was a secondary outcome. |
| Participants | Pregnant participants in ORIP |
| Form | DHA-dominant fish oil |
| Dose | Approximately 800 mg DHA and 100 mg EPA daily |
| Dose basis | Approximately 800 mg DHA and 100 mg EPA daily |
| Comparator | Vegetable oil with approximately 15 mg DHA and 4 mg EPA for masking |
| Duration | Started before week 20 of pregnancy; continued until week 34. |
| Confidence | 2/4: Secondary outcome without adjustment for multiplicity.; No grounds for a separate downgrade.; Measurement directly addresses the specified narrow PICO.; The CI includes a small increase in risk.; No specific data for a separate downgrade. |
| Evidence base | 1 randomized ORIP trial; 1 named publication on this outcome. |
| Sources | [7] |
In a small study of people taking warfarin, no clear difference in INR between fish oil and control was found.
| Parameter | Data |
|---|---|
| Result | In a small study of people taking warfarin, no clear difference in INR between fish oil and control was found. |
| Participants | People taking a stable warfarin dose |
| Form | Fish oil, total oil weight |
| Dose | 3 or 6 g oil daily |
| Dose basis | 3 or 6 g oil daily |
| Comparator | Placebo |
| Duration | 4 weeks |
| Confidence | 2/4: Five of 16 dropped out.; No grounds for a separate downgrade.; Measurement directly addresses the specified narrow PICO.; Small sample, CI not reported.; No specific data for a separate downgrade. |
| Evidence base | 1 small randomized trial; 1 named publication on this outcome. |
| Sources | [3] |
In seven large studies of different omega-3 preparations, atrial fibrillation was recorded more often than in control groups.
In seven large studies of different omega-3 preparations, atrial fibrillation was recorded more often than in control groups. [5]
Fish oil can cause an unpleasant aftertaste and digestive upset. A pooled analysis of different omega-3 preparations found no clear increase in bleeding. Results differed for high-dose prescription icosapent.
Fish oil can cause an unpleasant aftertaste and digestive upset. A pooled analysis of different omega-3 preparations found no clear increase in bleeding. Results differed for high-dose prescription icosapent. [1] [2]
With anticoagulants or fish allergy, compatibility depends on the specific product and medication regimen.
With anticoagulants or fish allergy, compatibility depends on the specific product and medication regimen. [3] [4] [2]
Sources
- Bleeding Risk in Patients Receiving Omega-3 Polyunsaturated Fatty Acids: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. https://pmc.ncbi.nlm.nih.gov/articles/PMC11179820/
- Omega-3 Fatty Acids - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. https://pubmed.ncbi.nlm.nih.gov/10767122/
- Are fish oil supplements safe in finned fish-allergic patients?. https://pubmed.ncbi.nlm.nih.gov/18926060/
- Effect of long-term marine Omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC9109217/
- Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC8693224/
- A Randomized Trial of Prenatal n−3 Fatty Acid Supplementation and Preterm Delivery. https://doi.org/10.1056/NEJMoa1816832
Methodology: Subpages evidence-led supplement pipeline v1